318 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
2 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
3 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
4 Recruiting A Pharmacokinetic Study of Melphalan in Children
Condition: Hematopoietic Stem Cell Transplantation
Intervention: Drug: Melphalan
5 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
6 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
7 Recruiting Study of Intravenous RXDX-107 in Patients With Solid Tumors
Condition: Solid Tumor
Intervention: Drug: RXDX-107
8 Recruiting A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: ABT-414;   Radiation: Radiation;   Drug: Temozolomide;   Drug: Placebo for ABT-414
9 Active, not recruiting Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
Condition: Multiple Myeloma
Interventions: Drug: rhTPO;   Drug: CTX;   Drug: -CSF
10 Recruiting Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Condition: Multiple Myeloma
Interventions: Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan;   Drug: Carfilzomib/dexamethasone maintenance;   Drug: Observation without carfilzomib/dexamethasone maintenance
11 Not yet recruiting Safety and Efficacy of Entospletinib (GS-9973) Combined With Vincristine (VCR) and VCR-based Combination Chemotherapy in Adult Participants With Non-Hodgkin Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: ENTO;   Drug: VCR;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Etoposide;   Drug: Filgrastim
12 Not yet recruiting Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Conditions: Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate
13 Recruiting Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
Interventions: Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
14 Not yet recruiting Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
15 Not yet recruiting Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Etoposide, Cyclophosphamide, Carboplatin
16 Not yet recruiting A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Olaparib;   Drug: Carboplatin;   Drug: Anthracycline;   Drug: Cyclophosphamide
17 Not yet recruiting Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Hepatosplenic T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage II Angioimmunoblastic T-cell Lymphoma;   Stage II Enteropathy-Associated T-Cell Lymphoma;   Stage III Angioimmunoblastic T-cell Lymphoma;   Stage III Enteropathy-Associated T-Cell Lymphoma;   Stage IV Angioimmunoblastic T-cell Lymphoma;   Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Lenalidomide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
18 Recruiting MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients
Condition: Kidney Failure, Chronic
Intervention: Biological: Mitomycin C-induced peripheral blood mononuclear cells (MICs)
19 Not yet recruiting Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Doxorubicin;   Drug: Ketoconazole;   Drug: Docetaxel;   Drug: Estramustine;   Drug: Degarelix
20 Recruiting Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Mitoxsnteone;   Drug: Thalidomide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years